Browsing Category
Pharma Industry News
4766 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the…
Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA)…
Amber Bio raises $26m to advance first-of-its-kind RNA editing platform
Amber Bio, a trailblazing biotechnology company, has launched with an oversubscribed $26 million seed financing round to pioneer…
XyloCor’s cardiovascular gene therapy XC001 passes Phase 1 with promising results
XyloCor Therapeutics, Inc., a company specializing in the development of gene therapies for cardiovascular diseases, announced that the…
BRENZAVVY proves effective in TheracosBio’s Phase 3 Type 2 diabetes study
TheracosBio announced the publication of a 24-week randomized, double-blind, placebo-controlled trial, proving Bexagliflozin’s effectiveness as an adjunct to…
Lupin Limited continues momentum in Q1 FY2024: Insights into earnings and sales
Pharmaceutical giant Lupin Limited reported its Q1 FY2024 financial performance, indicating a gross profit of INR 31,013 million,…
Granules India subsidiary completes FDA PADE inspection with zero observations
Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of Granules India Limited, situated in Chantilly, Virginia, USA,…
PIPE-791 enters clinical phase: Pipeline Therapeutics’ precision approach to neuroinflammation treatment
Pipeline Therapeutics, a clinical-stage biopharmaceutical firm specializing in precision neuroregeneration, has announced the initiation of dosing for the…
Phase 2 trial of RLS-0071 : ReAlta’s innovative approach to treating rare newborn disease
ReAlta Life Sciences, Inc., a clinical mid-stage biotech company focusing on rare life-threatening diseases, has announced the commencement…
Biogen to expand portfolio with $7.3bn acquisition of Reata Pharmaceuticals
Biogen Inc. (Nasdaq: BIIB) is set to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA) for $172.5 per share in…